The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1566
ISSUE 1566
February 25, 2019
Fostamatinib (Tavalisse) for ITP
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
February 25, 2019 (Issue: 1566)
The FDA has approved fostamatinib disodium
hexahydrate (Tavalisse – Rigel), the first spleen
tyrosine kinase (SYK) inhibitor, for oral treatment of
thrombocytopenia in adults with chronic immune
thrombocytopenia (ITP) who have had an insufficient
response to a previous treatment.
... more
- C Neunert et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.
- Two new drugs for chronic ITP. Med Lett Drugs Ther 2009; 51:10.
- A Newland et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy 2018; 10:9.
- J Bussel et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018; 93:921.
- JB Bussel et al. Long-term maintenance of platelet respnses in adult patients with persistent/chronic immune thrombocytopenia treated with fostamatinib: 1-year efficacy and safety results. Blood 2017; 130(suppl 1):16.
- Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Drug Interactions Flockhart Table. Indiana University School of Medicine. Available at: https://drug-interactions.medicine.iu.edu. Accessed February 13, 2019.
- Q Mao and JD Unadkat. Role of the breast cancer resistance protein (BRCP/ABCG2) in drug transport–an update. AAPS J 2015; 17:65.
- A Gessner et al. Clinical aspects of transporter-mediated drug-drug interactions. Clin Pharmacol Ther 2019 January 16 (epub).
- K McKeage and KA Lyseng-Williamson. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA. Drugs Ther Perspect 2018; 34:451.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: Analysource® Monthly. February 5, 2019. Reprinted with permission by First Databank, Inc. All rights reserved. ©2019. www.fdbhealth.com/policies/drug-pricing-policy.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Fostamatinib (Tavalisse) for ITP
Article code: 1566c
Electronic, downloadable article - $45
Article code: 1566c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian